Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.
The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran.
The advisory from the American Heart Association aggregates the research performed thus far on the use of omega-3 fatty acids in hypertriglyceridemia and recommends a dose of 4 g/d to observe a therapeutic effect.
Sandoz announced a voluntary recall of certain lots of Losartan Potassium and Ezetimibe prescription bottles due to not meeting federal standards for child-resistant packaging as required by the Poison Prevention Packaging Act.
Further studies are needed to identify other subgroups of patients with atherosclerosis who stand to gain substantial benefit from PCSK9 inhibition.
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
A significant number of overweight and obese young people who are classified as nonhypertensive by the European Society of Hypertension criteria have high blood pressure and increased cardiovascular risk, according to newer American Academy of Pediatrics guidelines.
There are modest associations between higher lipid levels and circulating leukocyte counts in humans.
Investigators evaluated the risk for recurrent cardiovascular events and clinical benefit with ezetimibe.
Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.